Genentech Seeking to Expand Tarceva into First-Line Setting in EGFR-Mutated NSCLC Patients

Data presented at ASCO this week showed that NSCLC patients with EGFR mutations who received Tarceva lived twice as long without their disease progressing compared to patients who received platinum-based chemotherapy, which is currently the standard of care for first-line NSCLC therapy.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.